MCF-7 Transfection Reagent (Breast Cancer, HTB-22)

$229.00$1,617.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #1765)$229.00
1.5 ml (Catalog #1766)$539.00
1.5 ml CRISPR (Catalog #2169)$739.00
8.0 ml (Catalog #7059)$1,617.00
SKU: MCF7

Description

NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.

Transfection Reagent for MCF-7 Cells (Breast Cancer Cells, HTB-22)

  • Proprietary cationic lipid formulation
  • High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, and plasmid DNA
  • Effective and robust intracellular delivery
  • Kit includes Transfection Enhancer reagent
  • Work in the presence of serum
  • A proven reagent for establishing stable cell lines
  • Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
  • Download PowerPoint presentation for MCF-7 cells transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems MCF-7 Transfection Protocol: [PDF]

Download MSDS: [PDF]

MCF-7 Cell Line:

Breast cancer remains the second primary cause of cancer deaths in females as well as the most commonly diagnosed cancer in women in the United States. According to the National Breast Cancer Foundation, every year more than 252,000 women in the country are diagnosed with breast cancer and over 40,000 will die. The MCF-7 cell line was derived from a 69-year-old Caucasian female in 1970 and is the most extensively studied and frequently used of all the human breast cancer cell lines. MCF-7 stands for Michigan Cancer Foundation – 7 (referring to the institute where in 1973 the cell line was discovered by Soule and associates). This cell line is a perfect model to study the pathway of malignant progression. Previous to MCF-7, no mammary cell line could live longer than a few months. MCF-7 has multiple characteristics of differentiated mammary epithelium, including the capability of forming domes and the ability to process estradiol via cytoplasmic estrogen receptors. TNF alpha inhibits the growth of MCF-7 breast cancer cells. Applying anti-estrogens can transform the secretion of insulin-like growth factor binding proteins. Cells from the MCF-7 breast cancer cell line are widely regarded as a near perfect model to examine the growth of malignant tumors. Altogen Biosystems produces pre-optimized high-efficiency transfection reagent kits for the MCF-7 breast cancer cell line.

Data:

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the MCF-7 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).

MCF7-cells-transfection-protocol

Figure 2. Protein expression of GAPDH in MCF-7 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into MCF-7 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

 

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
  • Mol Cell Biol. 2013 33(7). SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation … Madan et al [PDF]

Altogen Biosystems:

Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1765)
  • 1.5 ml (Catalog #1766)
  • 1.5 ml CRISPR (Catalog #2169)
  • 8.0 ml (Catalog #7059)

Additional information

Kit Size (Volume)

0.5 ml (Catalog #1765), 1.5 ml (Catalog #1766), 1.5 ml CRISPR (Catalog #2169), 8.0 ml (Catalog #7059)